148 related articles for article (PubMed ID: 22527351)
1. The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects.
Davis J; Langdon G; Layton G; Chong CL; Ndongo MN; Vourvahis M
Eur J Clin Pharmacol; 2012 Nov; 68(11):1567-72. PubMed ID: 22527351
[TBL] [Abstract][Full Text] [Related]
2. Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects.
Vourvahis M; Davis J; Wang R; Layton G; Choo HW; Chong CL; Tawadrous M
Antimicrob Agents Chemother; 2012 Aug; 56(8):4303-9. PubMed ID: 22644026
[TBL] [Abstract][Full Text] [Related]
3. Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers.
Vourvahis M; Wang R; Gruener DM; Bruce RD; Haider S; Tawadrous M
Drug Alcohol Depend; 2012 Nov; 126(1-2):183-8. PubMed ID: 22682979
[TBL] [Abstract][Full Text] [Related]
4. Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects.
Langdon G; Davis J; Layton G; Chong CL; Weissgerber G; Vourvahis M
Br J Clin Pharmacol; 2012 May; 73(5):768-75. PubMed ID: 22040521
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
de Jong J; Mitselos A; Jurczak W; Cordoba R; Panizo C; Wrobel T; Dlugosz-Danecka M; Jiao J; Sukbuntherng J; Ouellet D; Hellemans P
Pharmacol Res Perspect; 2020 Oct; 8(5):e00649. PubMed ID: 32945596
[TBL] [Abstract][Full Text] [Related]
6. Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
Sabo JP; Lang B; Elgadi M; Huang F
Antimicrob Agents Chemother; 2015 Jan; 59(1):514-9. PubMed ID: 25385099
[TBL] [Abstract][Full Text] [Related]
7. Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants.
Sechaud R; Gu H; Rahmanzadeh G; Taylor A; Chiparus O; Sharma GK; Breitschaft A; Menssen HD
Cancer Chemother Pharmacol; 2024 May; 93(5):439-453. PubMed ID: 38270613
[TBL] [Abstract][Full Text] [Related]
8. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.
Abel S; Russell D; Whitlock LA; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):19-26. PubMed ID: 18333862
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.
Vourvahis M; Langdon G; Labadie RR; Layton G; Ndongo MN; Banerjee S; Davis J
Antimicrob Agents Chemother; 2012 Feb; 56(2):887-92. PubMed ID: 22123705
[TBL] [Abstract][Full Text] [Related]
10. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
Macha S; Mattheus M; Pinnetti S; Woerle HJ; Broedl UC
Clin Drug Investig; 2013 May; 33(5):351-7. PubMed ID: 23512637
[TBL] [Abstract][Full Text] [Related]
11. Effects of the selective AMPA modulator NBI-1065845 on the pharmacokinetics of midazolam or ethinyl estradiol-levonorgestrel in healthy adults.
Lin S; Ionescu A; Maynard-Scott J; Kennedy M; Walling DP; Furey M; Singh JB
Clin Transl Sci; 2024 May; 17(5):e13791. PubMed ID: 38700236
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study.
Taekema-Roelvink ME; Swart PJ; Kuipers ME; Krauwinkel WJ; Visser N; Smulders RA
Clin Ther; 2005 Sep; 27(9):1403-10. PubMed ID: 16291413
[TBL] [Abstract][Full Text] [Related]
13. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.
Vourvahis M; Gleave M; Nedderman AN; Hyland R; Gardner I; Howard M; Kempshall S; Collins C; LaBadie R
Drug Metab Dispos; 2010 May; 38(5):789-800. PubMed ID: 20124396
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers.
Davis J; Hackman F; Ndongo MN; Choo H; Lewis D; Tawadrous M; Goodrich J; Langdon G
Clin Ther; 2010 Oct; 32(11):1889-95. PubMed ID: 21095483
[TBL] [Abstract][Full Text] [Related]
15. Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study.
Johnson-Agbakwu C; Brown L; Yuan J; Kissling R; Greenblatt DJ
Clin Ther; 2018 Jan; 40(1):64-73. PubMed ID: 29198449
[TBL] [Abstract][Full Text] [Related]
16. The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects.
Mohamed MF; Trueman S; Feng T; Friedman A; Othman AA
J Clin Pharmacol; 2019 Apr; 59(4):510-516. PubMed ID: 30500075
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals.
Wang X; Dowty ME; Tripathy S; Le VH; Huh Y; Curto M; Winton JA; O'Gorman MT; Chan G; Malhotra BK
Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):367-381. PubMed ID: 38554232
[TBL] [Abstract][Full Text] [Related]
18. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30).
Young A; Anzures-Cabrera J; Derks M
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):248-56. PubMed ID: 22456295
[TBL] [Abstract][Full Text] [Related]
19. The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam.
Wiesinger H; Klein S; Rottmann A; Nowotny B; Riecke K; Gashaw I; Brudny-Klöppel M; Fricke R; Höchel J; Friedrich C
Clin Pharmacol Ther; 2020 Oct; 108(4):798-807. PubMed ID: 32275771
[TBL] [Abstract][Full Text] [Related]
20. Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers.
Butler K; Teng R
Curr Med Res Opin; 2011 Aug; 27(8):1585-93. PubMed ID: 21692601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]